Hormone replacement therapy

Hormone replacement therapy has been studied in 1,019 papers since 1996: 30 trials and 364 observational studies in people, 5 in animals, 604 reviews; 509 in the past year. The newest story, Nov 17, 2026: “Longer reproductive span linked to lower osteoporosis risk”.

Intervention

1,019 papers study it851 findingsUpdated

MeSH

Research on it is growing 9% faster than aging research as a whole: 33 papers in the latest year counted

58 new papers in 30 daysSee all 1,018 papers on hormone replacement therapy

At a glance

Independent labs found the same change in people. 212 independent labs in 54 countries.

“Randomization to oral MHT did not increase CHD risk in participants with a history of treated hyperlipidemia or in untreated participants with favorable lipid profiles”
Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone TherapyObstetrics and gynecology2026doi:10.1097/aog.0000000000006381

80 of its findings point the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 212 independent labs in 54 countries
  • 80 findings against
  • Funders: National Institutes of Health and others
  • 54 of 580 findings with company ties
  • Human trial30
  • Humans363
  • Animals5
  • In silico6

19 studies gave hormone replacement therapy to people and measured what changed.

What changedDesignPeopleSource

down: Decreases menopause Rating Scale total scoreAdjusted mean difference −6.4; 95% CI −7.8 to −5.0

Trial6 months500 peopleWomen45–60 yearsMidlife adults; Moderate-to-severe menopausal syndromeJournal of Health Science and Reports, Nov 12, 2026

up: Increases antral follicle count

up: Increases ovarian volume

Randomized trial3 treatment cyclesDiminished ovarian reserveCombinatorial chemistry & high throughput screening, Oct 8, 2026

no change: Has no effect on coronary artery disease

Randomized trial16,608 peopleWomen50-79 yearsOlder adults; Midlife adults; Postmenopausal women; history of treated hyperlipidemia or untreated with favorable lipid profilesObstetrics and gynecology, Jul 23, 2026

down: Protects against menopausal symptoms

Trial24 months334 peopleWomenmean 39.2 yearsIn RRSO groupJAMA network open, Jul 1, 2026

down: Decreases menopausal symptoms

up: Improves quality of life

Trialthree months60 peopleWomen40-85 yearsMidlife adults; Older adults; Postmenopausal women; both partnership groupsFrontiers in global women's health, Jun 2, 2026

What did studies of hormone replacement therapy find?

269

Studies of hormone replacement therapy measured 269 outcomes; the most studied are menopausal symptoms (27 studies), quality of life (13) and mortality (11).

Menopausal symptoms

downin humans18upin humans7downin reviews1upin reviews1+83%

27 studies
  1. Hormone replacement therapy decreases menopausal symptoms in humans (both partnership groups).

    “HRT was associated with improvement in menopausal symptoms and quality of life in both groups.”

    Human trialboth partnership groupscombinedthree monthsfemalesn = 60

    Partnership as a modulator of the effects of hormone replacement therapy in menopause

    Frontiers in global women's health

  2. Hormone replacement therapy improves menopausal symptoms in humans (perimenopause or postmenopause) (3 of 5 women).

    “Three women reported relief of menopausal symptoms (eg, sleep disturbance, vasomotor symptoms, and joint pain), which was perceived as beneficial to mental stability.”

    Human trialperimenopause or postmenopause3 monthsfemalesn = 5

    Practical Approach to Hormone Replacement Therapy for (Peri) Menopausal Women With Schizophrenia Spectrum Disorders: A Case Series

    Schizophrenia bulletin

  3. Hormone replacement therapy decreases menopausal symptoms in humans (menopausal transition) (Greene scale score from 16.01±4.12 to 4.02±3.12 points).

    “the significantly decreased mean final Green's scale score was observed: from 17.12±3.28 to 6.12±4.34 points in group 1 and from 16.01±4.12 to 4.02±3.12 points in group 2.”

    Human trialmenopausal transition1 monthfemalesn = 16

    Non-hormonal correction of menopausal syndrome: potential of xenon therapy

    Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury

  4. Hormone replacement therapy is linked with better menopausal symptoms in humans (83.3%).

    “hormone therapy demonstrated superior effectiveness (83,3%) relative to non-hormonal modalities”

    Humansfemalesn = 105

    CLINICAL MANIFESTATIONS OF THE MENOPAUSAL TRANSITION AND THEIR IMPACT ON WOMEN’S QUALITY OF LIFE: RESULTS OF A QUESTIONNAIRE-BASED STUDY

    Neonatology surgery and perinatal medicine

  5. Hormone replacement therapy is linked with lower menopausal symptoms in humans (natural menopause; tibolone or isoflavones).

    “the women who participated and received HRT consisting of either tibolone or phytoestrogen isoflavones showed a significant and immediate reduction in symptoms”

    Humansnatural menopause; tibolone or isoflavones

    Comparison of Hormone Replacement Therapy in Women with Natural and Surgical Menopause: A Five-Year Experience in a Tertiary Greek Family Planning Center

    Obstetrics and gynecology.

  6. Hormone replacement therapy is linked with lower menopausal symptoms in humans (40.17 ± 6.04 at baseline to 11.38 ± 4.90 at 24 months).

    “The mean Kuppermann score demonstrated marked improvement, declining from 40.17 ± 6.04 at baseline to 11.38 ± 4.90 at 24 months (p < 0.001)”

    Humans24 monthsfemalesn = 809

    Real-world study on the effectiveness and breast safety analysis of hormone replacement therapy during menopause

    Frontiers in medicine

  7. Hormone replacement therapy is linked with less menopausal symptoms in humans (postmenopausal women).

    “in the six assessed health domains, menopausal hormone therapy (ever use) was found to be a protective factor”

    Humanspostmenopausal womenever usefemales

    Impact of hysterectomy without oophorectomy on the health of postmenopausal women: Assessment of physical, psychological, and cognitive factors

    Maturitas

  8. Hormone replacement therapy decreases menopausal symptoms in humans (individualized therapy in postmenopausal women).

    “individualized MHT can also improve skeletal outcomes while benefiting menopausal symptoms and overall quality of life”

    Reviewindividualized therapy in postmenopausal womenfemales

    Revisiting menopausal hormone therapy for bone health: evidence, controversies, and clinical positioning in India in 2026

    Archives of osteoporosis

  9. Hormone replacement therapy improves menopausal symptoms in humans.

    “Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor and genitourinary symptoms of menopause”

    Reviewfemales

    Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence

    Pharmacotherapy

  10. Hormone replacement therapy improves menopausal symptoms in humans (early and premature menopause induced by cancer treatment).

    “The most effective method for their prevention and symptoms relief is menopausal hormone therapy (MHT)”

    Reviewearly and premature menopause induced by cancer treatment

    Prescription of menopausal hormone therapy during and after completion of treatment for malignant tumors of the woman’s reproductive system: a systematic review of current clinical guidelines

    P A Herzen Journal of Oncology

All 27

Quality of life

upin humans13

13 studies
  1. Hormone replacement therapy improves quality of life in humans (both partnership groups).

    “HRT was associated with improvement in menopausal symptoms and quality of life in both groups.”

    Human trialboth partnership groupscombinedthree monthsfemalesn = 60

    Partnership as a modulator of the effects of hormone replacement therapy in menopause

    Frontiers in global women's health

  2. Hormone replacement therapy improves quality of life in postmenopausal women with osteopenia or osteoporosis.

    “found out reliable differences for 14 from 17 scales and to four domens in behalf of patients which accepted a hormone replacement therapy”

    Human trialin postmenopausal women with osteopenia or osteoporosis12 monthsfemales

    Women have features of quality of life with the different forms of osteoporosis

    Perinatology and reproductology from research to practice

  3. Hormone replacement therapy is linked with better quality of life in humans (post-RRSO).

    “Menopause related quality of life was higher in MHT users vs non-users.”

    Humanspost-RRSO24 monthsfemales

    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO)

    Gynecologic oncology

  4. Hormone replacement therapy improves quality of life in humans.

    “HRT can significantly improve quality of life and provide additional health benefits when used in an individualized manner”

    ReviewClimacteric and postmenopausal women; individualized therapy initiated at the appropriate timefemales

    Hormone replacement therapy (TRH) in quality of life and disease risk in climacteric and postmenopausal women

    Revista fisio&terapia.

  5. Hormone replacement therapy improves quality of life in humans (gynecologic cancer survivors).

    “Integrating menopause management into routine survivorship care is essential to optimize quality of life”

    Reviewgynecologic cancer survivors

    Hormone replacement therapy in gynecologic cancer survivors: bridging the gap between evidence and clinical practice

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

  6. Hormone replacement therapy improves quality of life in humans (menopause).

    “Significant improvements were also observed in vasomotor symptoms, sleep quality, psychological well-being, and sexual function, promoting better quality of life.”

    Reviewmenopausefemales

    Impact of hormone therapy on metabolic syndrome and quality of life in menopausal women

    RECIMA21 - Revista Científica Multidisciplinar

  7. Hormone replacement therapy improves quality of life in peri- and postmenopausal women.

    “improves the quality of life for peri- and postmenopausal women”

    Reviewin peri- and postmenopausal womenfemales

    Menopausal hormone therapy in patients with cardiovascular and metabolic diseases: an interdisciplinary Delphi consensus among Russian gynecologists, cardiologists, endocrinologists, gerontologists and geriatricians, phlebologists, and clinical pharmacologists

    Terapevticheskii arkhiv

  8. Hormone replacement therapy improves quality of life in humans (comorbid cardiovascular and metabolic diseases).

    “does not preclude the use of MHT to relieve menopausal symptoms and improve quality of life.”

    Reviewcomorbid cardiovascular and metabolic diseasesfemales

    Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG

    Problemy endokrinologii

  9. Hormone replacement therapy improves quality of life in humans.

    “Hormone replacement therapy has the potential to improve quality of life by treating bothersome symptoms and delaying the physical changes brought on by loss of estrogen.”

    Reviewfemales

    Menopause in Plastic Surgery Patients: An Underrecognized and Undertreated Comorbidity

    Plastic and reconstructive surgery

  10. Hormone replacement therapy improves quality of life in humans (administered from the onset of menopausal symptoms).

    “Hormone replacement therapy (HRT) administered from the onset of menopausal symptoms usually improves quality of life and life expectancy.”

    Reviewadministered from the onset of menopausal symptomsfemales

    Ovarian tissue cryopreservation and transplantation in menopause: new perspective of therapy in postmenopausal women and the importance of ethical and legal frameworks

    European review for medical and pharmacological sciences

All 13

Mortality

downin humans7no changein humans4HR 0.81–1.24

11 studies
  1. Hormone replacement therapy was not clearly linked with mortality in humans After fragility hip fracture surgery (13.8% versus 14.7%; P=0.97).

    “six-month mortality (13.8% vs. 14.7%; P=0.97) were similar between groups.”

    HumansAfter fragility hip fracture surgerysystemicSix months postoperativelyfemalesn = 358

    Menopausal Hormone Therapy History is Associated with Improved Postoperative Ambulatory Recovery in Postmenopausal Women with Hip Fragility Fractures

    Journal of orthopaedic trauma

  2. Hormone replacement therapy was not clearly linked with mortality in humans (1.6% vs 1.7%; HR 1.24, 95% CI 0.90–1.71).

    “HRT was not associated with significant differences in all-cause mortality (1.6% vs 1.7%; HR, 1.24; 95% CI, 0.90 to 1.71; p=0.18)”

    Humanspremature menopause; compared with no hormone replacement therapy after propensity score matching10 yearsfemales

    Hormone therapy not linked to fewer deaths after premature menopause

    AHA Scientific Sessions 2026 abstract

  3. Hormone replacement therapy is linked with lower mortality in humans after chemoradiotherapy for cervical cancer (HR 0.81 (95% CI 0.63-0.91)).

    “The use of hormone therapy was also associated with significantly improved overall survival (hormone therapy, 0.81; 95% confidence interval, 0.63-0.91).”

    Humansafter chemoradiotherapy for cervical cancerfemales

    Hormones linked to benefits in young advanced cervical cancer cohort

    American journal of obstetrics and gynecology

  4. Hormone replacement therapy is linked with lower mortality in postmenopausal women with chronic kidney disease.

    “the group exposed to hormone replacement therapy showed lower risks of major adverse cardiovascular events, kidney failure, and all-cause mortality.”

    Humansin postmenopausal women with chronic kidney diseasefemalesn = 768,279

    Potential benefits of hormone replacement therapy on cardiovascular and kidney outcomes in postmenopausal women with chronic kidney disease

    Journal of nephrology

  5. Hormone replacement therapy was not clearly linked with mortality in humans (death from breast cancer; current vs. never HRT use) (HR 0.85 (95% CI, 0.40, 1.78)).

    “did not associate with risk of death from BC (HR current vs. never, 0.85; 95% CI, 0.40, 1.78)”

    Humansdeath from breast cancer; current vs. never HRT usefemales

    Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study

    Clinical breast cancer

  6. Hormone replacement therapy decreases mortality in humans (timely initiated).

    “Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases.”

    Reviewtimely initiated

    Resolution of the VII International Forum of Experts on Menopausal Hormone Therapy

    Reproductive Endocrinology

  7. Hormone replacement therapy decreases mortality in humans within 10 years of menopause (-28%, RR=0.72, 95% CI 0.54-0.97).

    “beginning HRT at a younger age and within 10 years of menopause lowers all-cause mortality by 28% (RR=0.72, 95% CI 0.54-0.97)”

    Reviewwithin 10 years of menopause

    Cardiovascular risk in hormone replacement therapy

    Bleeding Thrombosis and Vascular Biology

  8. Hormone replacement therapy decreases mortality in postmenopausal HF patients (RR: 0.65, 95% CI: 0.49-0.87).

    “However, a significant reduction in all-cause mortality was observed among post-menopausal HF patients who received HRT (RR: 0.65, 95% CI: 0.49-0.87, p = 0.003).”

    Reviewin postmenopausal HF patientsfemales

    The Impact of Hormone Replacement Therapy on the Risk of Heart Failure in Postmenopausal Women: A Meta-Analysis of Clinical and Observational Studies

    Pharmacoepidemiology and drug safety

  9. Hormone replacement therapy showed no clear effect on mortality in humans after breast cancer diagnosis.

    “None of the studies, including HABITS, reported increased breast cancer mortality associated with HRT.”

    Reviewafter breast cancer diagnosis

    Hormone Replacement Therapy After Breast Cancer: It Is Time

    Cancer journal (Sudbury, Mass.)

  10. Hormone replacement therapy decreases mortality in humans (at or near menopause).

    “Initiated in women at younger than 60 years and/or at or near menopause, HRT significantly reduces all-cause mortality”

    Reviewat or near menopausefemales

    Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing

    Cancer journal (Sudbury, Mass.)

All 11

Vasomotor symptoms

downin humans6upin humans4

10 studies
  1. Hormone replacement therapy is linked with lower vasomotor symptoms in humans.

    “Results indicated significant improvement in vasomotor symptoms (hot flashes), insomnia, skin and vaginal dryness, hair loss, and osteoarticular pain.”

    Humanscombined estrogen-progestogen or estrogen-onlyfemalesn = 30

    Perceived Effects of Hormone Replacement Therapy on Menopausal Symptoms in Postmenopausal Women: a Cross-Sectional Study

    Journal of Health Sciences

  2. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Menopausal Hormone Therapy (MHT) is established as the most effective treatment, particularly when initiated within the “timing window” (aged <60 years or within 10 years of onset)”

    Reviewmenopausetransdermal

    Contemporary Management of Menopausal Vasomotor Symptoms: An Evidence-Based Review of Hormonal and Non-Hormonal Interventions

    Clinical and Experimental Obstetrics & Gynecology

  3. Hormone replacement therapy improves vasomotor symptoms in humans (menopause).

    “Menopausal Hormone Therapy (MHT) is the most effective treatment for vasomotor symptoms”

    Reviewmenopausefemales

    Good Clinical Practice Recommendations for Menopause Care in Pakistan Issuing Organization: Pakistan Menopause Society (PMS)

    Journal of The Society of Obstetricians and Gynaecologists of Pakistan

  4. Hormone replacement therapy improves vasomotor symptoms in humans (climacteric symptoms).

    “Hormone therapy was the most consistently represented effective option, particularly for vasomotor symptoms”

    Reviewclimacteric symptomsfemales

    Menopausal and Climacteric Symptoms, Risk Factors, and Treatment Options: Scoping Review with ☸SAIMSARA

    SAIMSARA Journal

  5. Hormone replacement therapy decreases vasomotor symptoms in humans (70-90% reduction).

    “Hormone therapy demonstrated superior efficacy for vasomotor symptoms (70-90% reduction) compared to lifestyle interventions”

    Review

    What is the comparative effectiveness of pharmacological versus lifestyle-based management strategies for menopausal symptoms in postmenopausal women? : A Systematic Review

    The Indonesian Journal of General Medicine

  6. Hormone replacement therapy improves vasomotor symptoms in humans.

    “menopausal hormone therapy remains the most effective treatment for vasomotor symptoms”

    Reviewfemales

    Optimizing Healthspan in Women: A New Paradigm for Successful Aging through the Menopausal Transition

    Journal of menopausal medicine

  7. Hormone replacement therapy decreases vasomotor symptoms in humans (selected women with premature menopause without contraindications).

    “Menopausal hormone therapy (MHT) should be considered for premature menopause management in selected women without contraindications, improving both vasomotor symptoms and sleep quality.”

    Reviewselected women with premature menopause without contraindicationsfemales

    Insomnia in Women Surviving Breast and Gynecological Cancers-A Narrative Review to Address the Hormonal Factor

    Cancers

  8. Hormone replacement therapy decreases vasomotor symptoms in humans.

    “Current evidence from clinical studies and meta-analyses unequivocally demonstrates that hormone replacement therapy is the most efficacious treatment for vasomotor and urogenital symptoms”

    Reviewfemales

    Reconsidering Hormone Replacement Therapy: Current Insights on Utilisation in Premenopausal and Menopausal Women: An Overview

    Journal of clinical medicine

  9. Hormone replacement therapy improves vasomotor symptoms in humans (menopause in women with a history of endometriosis).

    “Menopausal hormone therapy (MHT) is indicated for managing vasomotor and genitourinary symptoms and maintaining bone health.”

    Reviewmenopause in women with a history of endometriosisfemales

    Endometriosis and menopausal health: An EMAS clinical guide

    Maturitas

  10. Hormone replacement therapy decreases vasomotor symptoms in humans.

    “MHT consistently alleviates vasomotor symptoms”

    Reviewfemales

    Menopausal hormone theraphy – application, risks and benefits in clinical practice

    International Journal of Innovative Technologies in Social Science

Vasomotor symptoms

downin humans9

9 studies
  1. Hormone replacement therapy decreases vasomotor symptoms in humans (eligible women after risk-reducing salpingo-oophorectomy).

    “For eligible women, menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and prevents estrogen‐deficiency bone loss.”

    Revieweligible women after risk-reducing salpingo-oophorectomyfemales

    From cancer prevention to survivorship: Comprehensive menopause management after risk‐reducing salpingo‐oophorectomy

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

  2. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms”

    Reviewmenopause

    From Established Care to Precision Menopause Medicine: A Clinical-Actionability Framework for Contemporary Menopause Management

    Journal of clinical medicine

  3. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Hormone replacement therapy (HRT) remains the most effective treatment for vasomotor symptoms”

    Reviewmenopausefemales

    Hormone replacement therapy: an overview for South African pharmacists

    SA pharmaceutical journal.

  4. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “THM is the most effective treatment for vasomotor symptoms.”

    Reviewmenopausefemales

    Management of menopausal symptoms

    FMC - Formación Médica Continuada en Atención Primaria

  5. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause) (efficacy exceeds eighty percent).

    “The results demonstrate that efficacy in controlling vasomotor symptoms exceeds eighty percent.”

    Reviewmenopausefemales

    HORMONE THERAPY IN MENOPAUSE: EVALUATION OF BENEFITS AND RISKS

    Asclepius International Journal of Scientific Health Science

  6. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “MHT provides the most effective relief of vasomotor symptoms”

    Reviewmenopausefemales

    Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review

    International journal of molecular sciences

  7. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause) (70%-90% reduction).

    “Hormonal therapies (MHT/HRT), evolved from WHI trials, effectively reduce VMS by 70%-90%”

    Reviewmenopausefemales

    Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management

    Frontiers in reproductive health

  8. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).

    “Menopausal hormonal therapy (MHT) is supported by level 1 evidence and can address many of the negative impacts associated with menopause, including VMS.”

    Reviewmenopausefemales

    Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms

    Drugs

  9. Hormone replacement therapy decreases vasomotor symptoms in humans (menopause transition).

    “its value in the treatment of disabling vasomotor symptoms is still undisputed.”

    Reviewmenopause transitionfemales

    Hormone therapy and cardiovascular disease: Benefits and harms

    Best practice & research. Clinical endocrinology & metabolism

More on Vasomotor symptoms

Cognitive function

upin humans3no changein humans3downin humans1downin silico1

8 studies
  1. Hormone replacement therapy was not clearly linked with cognitive function in humans.

    “there was insufficient evidence to support a causal association between HRT use and cognitive decline.”

    HumansGenetically predicted use, after adjustment for premature menopause, premature ovarian insufficiency, age at HRT initiation, and duration of use

    Causal effects of reproductive traits on cognitive function: A two-sample and multivariable mendelian randomization study

    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

  2. Hormone replacement therapy is linked with worse cognitive function in humans (indirect effect through regional tau accumulation).

    “with an indirect effect of HT on cognitive decline through regional tau accumulation”

    Humansindirect effect through regional tau accumulationfemales

    Associations between hormone therapy use and tau accumulation in brain regions vulnerable to Alzheimer's disease

    Science advances

  3. Hormone replacement therapy was not clearly linked with cognitive function in humans (postmenopausal women followed ~10 years post-trial).

    “Tests assessing the effects of mHT allocation on cognitive slopes during the KEEPS and across all years of follow-up including the KEEPS Continuation visit were all statistically nonsignificant.”

    Humanspostmenopausal women followed ~10 years post-trial10 yearsfemalesn = 275

    Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study

    PLoS medicine

  4. Hormone replacement therapy improves cognitive function in humans (menopause).

    “Menopausal hormone therapy may improve cognition”

    Reviewmenopausefemales

    Treatment of Menopause-Related Cognitive Dysfunction and Brain Fog

    Psychiatric Annals

  5. Hormone replacement therapy improves cognitive function in humans (premature ovarian insufficiency).

    “Hormone therapy has heterogenous effects with cognitive benefit in premature ovarian insufficiency”

    Reviewpremature ovarian insufficiencyfemales

    The Neurology of Menopause

    Current neurology and neuroscience reports

  6. Hormone replacement therapy showed no clear effect on cognitive function in humans (young menopausal women).

    “Menopausal hormone therapy in young menopausal women was not shown to have beneficial effects on cardiovascular disease, cancer, depression, or cognition”

    Reviewyoung menopausal womenfemales

    The effects of menopausal hormone therapy on cardiovascular disease, cancer, cognition and depression in younger women: A systematic review

    JRSM open

  7. Hormone replacement therapy improves cognitive function in humans (initiated early in menopausal transition for menopausal symptoms).

    “MHT initiated early in the menopausal transition for menopausal symptoms has the strongest evidence for sustaining cognitive function and reducing Alzheimer's risk.”

    Reviewinitiated early in menopausal transition for menopausal symptomsfemales

    Sex Hormone Therapies and Alzheimer's Disease: Prevention vs Treatment

    AAIC 2025 abstract

  8. Hormone replacement therapy impairs cognitive function in silico.

    “HRT use was associated with slower performance in Pairs Matching and lower scores in Symbol Digit Substitution tests.”

    In silico

    Strengthening the Evidence for a Causal Link between Reproductive Traits and Cognitive Function: Insights from Two‐Sample and Multivariable Mendelian Randomization

    AAIC 2025 abstract

Breast cancer

no changein humans7no changein reviews1HR 1.01

8 studies
  1. Hormone replacement therapy was not clearly linked with breast cancer in humans after chemoradiotherapy for cervical cancer.

    “There were no significant differences in incidences of thromboembolism, breast cancer, or colorectal cancer.”

    Humansafter chemoradiotherapy for cervical cancerfemales

    Hormones linked to benefits in young advanced cervical cancer cohort

    American journal of obstetrics and gynecology

  2. Hormone replacement therapy was not clearly linked with breast cancer in humans (peri-menopausal women with pre-existing MASLD).

    “HRT was not associated with increased risk of breast cancer or VTE”

    Humansperi-menopausal women with pre-existing MASLD5 yearsfemales

    Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD

    Liver international : official journal of the International Association for the Study of the Liver

  3. Hormone replacement therapy was not clearly linked with breast cancer in humans (breast cancer familial risk score of 0.4 or higher) (HR 1.01 (95% CI 0.82 to 1.25)).

    “1.01 (95% CI = 0.82 to 1.25) for a breast cancer familial risk score of 0.4 or higher”

    Humansbreast cancer familial risk score of 0.4 or higherfemales

    Menopausal hormone therapy: assessing associations with breast and colorectal cancers by familial risk

    JNCI cancer spectrum

  4. Hormone replacement therapy was not clearly linked with breast cancer in humans (hazard ratio 0.312; 95% CI 0.039 to 2.480; p=0.278).

    “revealed no significant difference in the risk of breast cancer between these two groups”

    HumansBRCA1 or BRCA2 mutation carriers after risk-reducing salpingo-oophorectomy, adjusted for age and paritymedian follow-up 3.03 yearsfemalesn = 151

    Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea

    Cancer research and treatment

  5. Hormone replacement therapy showed no clear effect on breast cancer (BRCA mutation carriers after risk-reducing salpingo-oophorectomy; short course).

    “a short course of hormone replacement therapy does not increase breast cancer risk in BRCA mutation carriers after risk-reducing salpingo-oophorectomy”

    ReviewBRCA mutation carriers after risk-reducing salpingo-oophorectomy; short courseshort coursefemales

    Hormone replacement therapy in healthy BRCA1 and 2 mutation carriers after risk-reducing salpingo-oophorectomy: A 5 Ws and 2 Hs practitioner toolkit

    Maturitas

  6. Hormone replacement therapy showed no clear effect on breast cancer in naturally or surgically menopausal women.

    “estrogen-alone HRT has little impact on breast cancer risk in naturally or surgically menopausal women”

    Reviewin naturally or surgically menopausal womenestrogen-alonefemales

    Estrogens and breast cancer

    Annals of oncology : official journal of the European Society for Medical Oncology

  7. Hormone replacement therapy showed no clear effect on breast cancer in humans (non-randomized prospective observational studies in breast cancer survivors).

    “no increased risk of recurrence was reported in the observational studies”

    Reviewnon-randomized prospective observational studies in breast cancer survivorsbreastfemales

    Menopausal Hormone Therapy in Breast Cancer Survivors

    Cancers

  8. Hormone replacement therapy showed no clear effect on breast cancer in humans (early menopause after preventive surgery, including BRCA1 and BRCA2 carriers).

    “HRT for women in early menopause does not increase breast cancer risk, including in those who are BRCA1 and BRCA2 carriers and have preventative surgery.”

    Reviewearly menopause after preventive surgery, including BRCA1 and BRCA2 carriersfemales

    Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66

    BJOG : an international journal of obstetrics and gynaecology

More on Breast cancer

Bone mineral density

upin humans5downin humans1no changein humans1

7 studies
  1. Hormone replacement therapy was not clearly linked with bone mineral density in humans across HRT regimes in CAIS.

    “The expanded sub-analysis on 73 women confirmed no significant differences in BMD across HRT regimes.”

    Humansacross HRT regimes in CAISbonefemalesn = 73

    Bone health in complete androgen insensitivity syndrome: a comprehensive assessment in a large adult cohort

    European journal of endocrinology

  2. Hormone replacement therapy is linked with better bone mineral density in humans.

    “The 24-month MHT regimen effectively improved BMD, alleviated menopausal symptoms in a stage-dependent manner”

    Humansbone24 monthsfemalesn = 809

    Real-world study on the effectiveness and breast safety analysis of hormone replacement therapy during menopause

    Frontiers in medicine

  3. Hormone replacement therapy is linked with higher bone mineral density in humans (mesial/distal sites; differences not all significant).

    “the mesial/distal BMD was higher in patients in the HRT group than those in the control group”

    Humansmesial/distal sites; differences not all significantfemales

    Hormone Replacement Therapy Relieves Periodontitis by Inhibiting Alveolar Bone Loss and Inflammation

    Oral diseases

  4. Hormone replacement therapy protects against bone mineral density in humans after surgery.

    “Hormone therapy reduced but did not always eliminate this decline.”

    Reviewafter surgeryfemales

    PREMATURE OVARIAN INSUFFICIENCY AFTER BILATERAL OOPHORECTOMY: LONG-TERM SKELETAL OUTCOMES AND FRACTURE RISK

    Revista de Geopolítica

  5. Hormone replacement therapy improves bone mineral density in postmenopausal women.

    “HRT can reduce bone loss by compensating for estrogen deficiency and has been shown to improve BMD and reduce fracture risk.”

    Reviewin postmenopausal women

    Comprehensive review of postmenopausal osteoporosis: molecular mechanisms, lifestyle interventions and pharmacological advances

    International Journal of Research in Medical Sciences

  6. Hormone replacement therapy increases bone mineral density in humans (compared with exercise therapy alone) (greater improvements than exercise therapy alone; no numbers given).

    “there were greater improvements in BMD than exercise therapy alone”

    Reviewcompared with exercise therapy alonebonefemales

    Comparative Effects of Hormone Replacement Therapy and Exercise on Bone Health in Postmenopausal Women: A Systematic Review

    Cureus

  7. Hormone replacement therapy improves bone mineral density in humans (menopausal women).

    “MHT and exercise are effective in preserving BMD in menopausal women.”

    Reviewmenopausal womenfemales

    Impact of menopause hormone therapy, exercise, and their combination on bone mineral density and mental wellbeing in menopausal women: a scoping review

    Frontiers in reproductive health

More on Bone mineral density

Menopausal symptoms

downin humans5downin reviews1

6 studies
  1. Hormone replacement therapy protects against menopausal symptoms in RRSO group.

    “When restricted to the RRSO group who took hormone replacement therapy, there was no significant worsening of total sexual function scores or menopausal symptoms compared with baseline.”

    Human trialin RRSO groupfemales

    Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial

    JAMA network open

  2. Hormone replacement therapy decreases menopausal symptoms in humans (menopausal symptoms).

    “Hormone replacement therapy is the most effective treatment for menopausal symptoms”

    Reviewmenopausal symptoms

    Discontinuing and reintroducing hormone replacement therapy

    Independent Nurse

  3. Hormone replacement therapy decreases menopausal symptoms in humans.

    “Currently, the most effective treatment for these symptoms is menopausal hormone therapy (MHT).”

    Reviewfemales

    Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and Metabolic Diseases. Consensus Document of RSC, RSOG, RAE, EUAT, RAP, RSMSI, RAGG

    Kardiologiia

  4. Hormone replacement therapy decreases menopausal symptoms in humans.

    “While menopausal hormone therapy (MHT) is the most effective treatment, contraindications such as estrogen-sensitive cancers and thromboembolic conditions limit its use for many women”

    Reviewfemales

    Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated

    Seminars in reproductive medicine

  5. Hormone replacement therapy decreases menopausal symptoms in humans.

    “The efficacy of menopausal hormone therapy for bothersome menopausal symptoms is well established.”

    Reviewfemales

    Menopausal hormone therapy in women with benign gynaecological conditions and cancer

    Best practice & research. Clinical endocrinology & metabolism

  6. Hormone replacement therapy decreases menopausal symptoms.

    “Hormone replacement therapy has been shown to be effective in alleviating menopausal symptoms.”

    Review

    Bioidentical hormone therapy in menopause: relevance in dermatology

    Dermatology online journal

More on Menopausal symptoms

Osteoporosis

downin humans5

5 studies
  1. Hormone replacement therapy is linked with lower osteoporosis in humans (18.0% to 14.0%).

    “the prevalence of osteoporosis and low bone mass decreased significantly from 18.0 to 14.0% and from 27.4 to 21.4%, respectively (p < 0.001)”

    Humansbone24 monthsfemalesn = 809

    Real-world study on the effectiveness and breast safety analysis of hormone replacement therapy during menopause

    Frontiers in medicine

  2. Hormone replacement therapy protects against osteoporosis in humans (premature menopause).

    “Menopausal hormone therapy (MHT) mitigates these risks and is recommended for individuals with premature menopause.”

    Reviewpremature menopause

    Granulosa cell tumors and menopausal hormone therapy: A narrative review

    Gynecologic oncology reports

  3. Hormone replacement therapy prevents osteoporosis in hypogonadal women.

    “In hypogonadal women, postmenopausal hormone replacement therapy (HRT) is key forosteoporosis prevention.”

    Reviewin hypogonadal womenfemales

    Impact of estroprogestin therapies on bone health from adolescence to postmenopause

    Journal of endocrinological investigation

  4. Hormone replacement therapy decreases osteoporosis in humans.

    “Benefits also included alleviation of mood disorders, insomnia, sexual dysfunction, cardiovascular issues, and osteoporosis.”

    Review

    SAT-819 What Kind of Specialists Should Know About Hormone Therapy?

    ENDO 2025 abstract

  5. Hormone replacement therapy prevents osteoporosis in humans.

    “Hormonal replacement therapy is effective in osteoporosis prevention”

    Review

    Muscle and Bone Health in Postmenopausal Women: Role of Protein and Vitamin D Supplementation Combined with Exercise Training

    Nutrients

More on Osteoporosis

Coronary artery disease

downin humans2no changein humans1

3 studies
  1. Hormone replacement therapy showed no clear effect on coronary artery disease in humans (history of treated hyperlipidemia or untreated with favorable lipid profiles).

    “Randomization to oral MHT did not increase CHD risk in participants with a history of treated hyperlipidemia or in untreated participants with favorable lipid profiles”

    Human trialhistory of treated hyperlipidemia or untreated with favorable lipid profilesoralfemales

    Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy

    Obstetrics and gynecology

  2. Hormone replacement therapy protects against coronary artery disease in humans (timing of hormone replacement therapy initiation).

    “estrogen may have an important protective role in CHD, particularly in women initiating treatment below age 60 years”

    Reviewtiming of hormone replacement therapy initiationfemales

    Primary prevention of coronary heart disease in women

    Post reproductive health

  3. Hormone replacement therapy protects against coronary artery disease in humans (started early after menopause (timing hypothesis)).

    “Recent evidence supports the cardioprotective effects of HRT when started early after menopause, ideally within ten years or before the age of sixty, in line with the "timing hypothesis".”

    Reviewstarted early after menopause (timing hypothesis)

    Terapia ormonale sostitutiva e terapie ormonali

    Cardiologia Ambulatoriale

More on Coronary artery disease

IL-1β

downin humans1

1 study
  1. Hormone replacement therapy decreases IL-1β in humans (oral MHT) (from 0.46 (0.26; 0.66) pg/mL to 0.26 (0.06; 0.56) pg/mL).

    “In addition, a significant reduction in IL-1β levels from 0.46 (0.26; 0.66) pg/mL to 0.26 (0.06; 0.56) pg/mL (p = 0.039) was observed after 12 weeks of oral MHT ( a).”

    Human trialoral MHT12 weeksn = 27

    Effect of Menopausal Hormone Therapy on Cellular Immunity Parameters and Cytokine Profile

    Biomedicines

  2. Hormone replacement therapy decreases IL-1β in menopausal patients.

    “oral MHT resulted in a significant decrease in IL-1β level”

    Human trialin menopausal patientsoralfemales

    Effect of Menopausal Hormone Therapy on Cellular Immunity Parameters and Cytokine Profile

    Biomedicines

More on IL-1β

MCP-1

downin humans1

1 study
  1. Hormone replacement therapy decreases MCP-1 in humans (oral and transdermal MHT) (from 10.23 (6.90; 13.96) pg/mL to 8.71 (5.39; 11.71) pg/mL and from 11.32 (9.53; 12.81) pg/mL to 8.72 (6.21; 12.29) pg/mL).

    “According to the data presented, after 12 weeks of using both oral and transdermal MHT in women, there was a significant decrease in the level of MCP-1 from 10.23 (6.90; 13.96) pg/mL to 8.71 (5.39; 11.71) pg/mL (p = 0.022) and from 11.32 (9.53; 12.81) pg/mL to 8.72 (6.21; 12.29) pg/mL (p = 0.026), respectively”

    Human trialoral and transdermal MHT12 weeksfemalesn = 50

    Effect of Menopausal Hormone Therapy on Cellular Immunity Parameters and Cytokine Profile

    Biomedicines

  2. Hormone replacement therapy decreases MCP-1 in menopausal patients.

    “different routes of MHT administration led to significant changes in monocyte phenotype and a decrease in monocyte chemoattractant protein-1 (MCP-1) level in menopausal patients”

    Human trialin menopausal patientsoral or transdermalfemales

    Effect of Menopausal Hormone Therapy on Cellular Immunity Parameters and Cytokine Profile

    Biomedicines

More on MCP-1

Menopause Rating Scale total score

downin humans1

1 study
  1. Hormone replacement therapy decreases menopause Rating Scale total score in humans (Moderate-to-severe menopausal syndrome; compared with integrative care) (Adjusted mean difference −6.4; 95% CI −7.8 to −5.0).

    “HRT produced more rapid symptomatic improvement at 6 months (adjusted mean difference −6.4; 95% confidence interval −7.8 to −5.0; p < 0.001).”

    Human trialModerate-to-severe menopausal syndrome; compared with integrative care6 monthsfemalesn = 500

    Hormone therapy linked to faster menopause symptom relief

    Journal of Health Science and Reports

Ovarian volume

upin humans1

1 study
  1. Hormone replacement therapy increases ovarian volume in humans.

    “AFC, ovarian volume, and E2 all increased significantly in both groups compared with baseline (P < 0.05).”

    Human trialDiminished ovarian reserve; combined with acupoint catgut embedding or sham acupoint embedding; compared with baselineovary3 treatment cycles

    Efficacy and Safety of Acupoint Catgut Embedding Combined with Hormone Replacement Therapy versus Sham Acupoint Embedding Combined with Hormone Replacement Therapy for Diminished Ovarian Reserve: A Single-Blind Randomized Controlled Trial

    Combinatorial chemistry & high throughput screening

All 269

What is hormone replacement therapy linked with?

251

Studies link hormone replacement therapy with 251 measures, most often breast cancer (22 studies), cardiovascular disease (13) and bone fracture (11).

Breast cancer

upin humans16downin humans3upin reviews2mixedin humans1HR 0.786–1.67

22 studies
  1. Hormone replacement therapy is linked with a lower risk of breast cancer in humans (menopause at age ≤60 years; propensity-matched new users vs non-users) (HR 0.786, 95% CI 0.743-0.831).

    “lower hazards of breast cancer (events: 1281 vs 1504; crude incidence: 1.53% vs 1.80%; HR: 0.786, 95% CI: 0.743-0.831)”

    Humansmenopause at age ≤60 years; propensity-matched new users vs non-usersestrogen and/or progestogenfemalesn = 83,670

    Long-term systemic outcomes of postmenopausal hormone replacement therapy by age at menopause: a real-world cohort study

    Human reproduction open

  2. Hormone replacement therapy is linked with a higher risk of breast cancer in prior pre-eclamptic women (1.25, 1.12-1.40).

    “MHT use was accompanied with comparable BC risk rise in prior pre-eclamptic and control women (1.25, 1.12-1.40 vs. 1.30, 1.18-1.42).”

    Humansin prior pre-eclamptic women

    Reduced Breast Cancer Risk in Women With A History of Pre-Eclampsia: Implications of Postmenopausal Hormone Therapy

    The Journal of clinical endocrinology and metabolism

  3. Hormone replacement therapy is associated with breast cancer in humans (adjusted multivariable logistic regression models) (ORa 6.052-7.146; p = 0.010-0.031).

    “The use of hormone replacement therapy (HRT) was significantly associated with breast cancer history (ORa 6.052-7.146, p = 0.010-0.031)”

    Humansadjusted multivariable logistic regression modelsfemalesn = 380

    A Cross-Sectional Analysis of Women Attending a Free Screening Mammography Campaign at a University Hospital in Lebanon

    International journal of women's health

  4. Hormone replacement therapy is linked with a lower risk of breast cancer in BRCA1 or BRCA2 carriers, exposed versus unexposed matched women (12.9% versus 18.9% incident cases).

    “there were 87 (12.9%) incident breast cancer cases in the 676 exposed women and 128 (18.9%) cases in the 676 unexposed women (P = .002)”

    Humansin BRCA1 or BRCA2 carriers, exposed versus unexposed matched womenfemalesn = 676

    Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2

    Journal of the National Cancer Institute

  5. Hormone replacement therapy is linked with a higher risk of breast cancer in humans (Current users compared with never users) (HR 1.44 (95% CI 1.36–1.52)).

    “MHT use was associated with increased risk of overall, luminal A-like, and luminal B-like breast cancer”

    HumansCurrent users compared with never usersestrogen-progestin therapyfemales

    Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study

    Breast cancer research : BCR

  6. Hormone replacement therapy is linked with a higher risk of breast cancer in humans (AOR 5.02, 95 % CI: 1.93-13.06).

    “Women who used hormone replacement therapy (HRT) were significantly associated with higher odds (5 folds) of having breast ca versus those who did not use them (AOR 5.02, 95 % CI: 1.93-13.06, p = 0.001).”

    Humansfemales

    Reproductive factors and breast cancer risk in Palestine: A case control study

    Cancer epidemiology

  7. Hormone replacement therapy is linked with a higher risk of breast cancer in humans (RR 1.26, 95% CI 1.20-1.32).

    “ever taking hormone replacement therapy 1.26 (1.20, 1.32)”

    Humansbreastfemales

    Factors for the Primary Prevention of Breast Cancer: A Meta-Analysis of Prospective Cohort Studies

    Journal of research in health sciences

  8. Hormone replacement therapy is linked with a higher risk of breast cancer in humans (current vs. never HRT use) (HR 1.67 (95% CI, 1.33, 2.11)).

    “The total current HRT use was associated with an increased risk of BC (HR current vs. never, 1.67; 95% CI, 1.33, 2.11)”

    Humanscurrent vs. never HRT usefemales

    Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study

    Clinical breast cancer

  9. Hormone replacement therapy is linked with a lower risk of breast cancer in humans (versus control patients) (0.26% vs 1.38%, p<=0.004).

    “the breast cancer risk in bisphosphonates ever use group (12/2326, 0.52%), statins ever use group (99/15287, 0.65%), hormone users for menopausal symptoms (20/7631, 0.26%) are significantly lower than control patients”

    Humansversus control patientsfemalesn = 7,631

    Differential effects of bisphosphonates and denosumab on primary breast cancer risk, potentially to be modified by statins

    Preprint

  10. Hormone replacement therapy is associated with breast cancer in humans.

    “The effect of menopausal hormone therapy on breast cancer risk is shown to vary according to the hormonal regimen and duration of exposure.”

    Review

    THE ROLE OF HORMONAL THERAPY IN THE DEVELOPMENT OF BREAST CANCER IN THE POSTMENOPAUSAL PERIOD

    Journal of modern medicine

All 22

More on Breast cancer

Cardiovascular disease

downin humans7mixedin humans3upin humans3HR 0.699–1.74

13 studies
  1. Hormone replacement therapy is linked with a lower risk of cardiovascular disease in humans (perimenopausal and recently postmenopausal women with vasomotor symptoms) (aHR 0.78, 95% CI 0.62-0.98).

    “adjusted hazard ratio (aHR) of CVD events for MHT initiation vs noninitiation was 0.78 (95% CI, 0.62-0.98)”

    Humansperimenopausal and recently postmenopausal women with vasomotor symptoms20-year follow-upfemalesn = 2,737

    Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms

    JAMA internal medicine

  2. Hormone replacement therapy is linked with a lower risk of cardiovascular disease in humans (menopause at age ≤60 years; propensity-matched new users vs non-users) (HR 0.699, 95% CI 0.688-0.709).

    “and CVD (events: 3960 vs 4413; crude incidence: 4.74% vs 5.29%; HR: 0.699, 95% CI: 0.688-0.709)”

    Humansmenopause at age ≤60 years; propensity-matched new users vs non-usersestrogen and/or progestogenfemalesn = 83,670

    Long-term systemic outcomes of postmenopausal hormone replacement therapy by age at menopause: a real-world cohort study

    Human reproduction open

  3. Hormone replacement therapy is associated with cardiovascular disease in humans (women veterans; compared with no menopausal hormone therapy) (HR 1.74, 95% CI 1.63–1.85).

    “HT was independently associated with a greater risk of CVD (HR = 1.74, 95% CI: 1.63-1.85)”

    Humanswomen veterans; compared with no menopausal hormone therapyoral or transdermal estrogen-containing product or combined estrogen-progestinfemales

    Association of menopausal hormone therapy with incident cardiovascular disease in women veterans

    European heart journal. Quality of care & clinical outcomes

  4. Hormone replacement therapy is associated with cardiovascular disease in humans (Prior pre-eclampsia; compared with MHT non-users) (HR 0.85, 95% CI 0.78–0.91).

    “The use of MHT in prior pre-eclamptic women was associated with significant risk reductions for any CVD (HR 0.85, 95 % CI 0.78-0.91)”

    HumansPrior pre-eclampsia; compared with MHT non-usersMean follow-up 13.3 yearsfemales

    Prior pre-eclampsia does not diminish the vascular protective effect of menopausal hormone therapy

    Maturitas

  5. Hormone replacement therapy is associated with cardiovascular disease in humans.

    “Menopausal Hormonal Therapy (THM) is a potential therapy to reduce CVD risk, though clinical trials have shown conflicting results”

    Reviewfemales

    Role of menopause in the development of cardiovascular disease in women

    Open heart

  6. Hormone replacement therapy lowers the risk of cardiovascular disease in humans (when prescribed on an individualized basis and initiated early).

    “It was also observed that hormone therapy may offer cardiovascular benefits when prescribed on an individualized basis and initiated early.”

    Reviewwhen prescribed on an individualized basis and initiated early

    Cardiovascular Risk During Menopause

    Open Minds International Journal

  7. Hormone replacement therapy raises the risk of cardiovascular disease in humans (established cardiovascular disease).

    “randomized trials showed no cardiovascular benefit, and in some cases, increased risks of coronary events, stroke, and venous thromboembolism”

    Reviewestablished cardiovascular diseasefemales

    Menopausal Hormone Therapy and Cardiovascular Risk: Current Evidence and Clinical Implications

    Medical sciences (Basel, Switzerland)

  8. Hormone replacement therapy lowers the risk of cardiovascular disease in humans (early initiation within 10 years of menopause onset).

    “Early initiation of HRT within 10 years of menopause onset consistently demonstrates cardiovascular benefits”

    Reviewearly initiation within 10 years of menopause onsetfemales

    Hormone replacement therapy and cardiovascular risk in postmenopausal women

    European heart journal open

  9. Hormone replacement therapy lowers the risk of cardiovascular disease in humans within 10 years of menopause (-40%, RR=0.60, 95% CI 0.41-0.86).

    “reduces cardiovascular events by 40% (RR=0.60, 95% CI 0.41-0.86)”

    Reviewwithin 10 years of menopause

    Cardiovascular risk in hormone replacement therapy

    Bleeding Thrombosis and Vascular Biology

  10. Hormone replacement therapy raises the risk of cardiovascular disease in humans (later initiation).

    “whereas later initiation may increase cardiovascular risk”

    Reviewlater initiationfemales

    The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review

    Frontiers in reproductive health

All 13

More on Cardiovascular disease

Bone fracture

downin humans10downin reviews1RR 0.72

11 studies
  1. Hormone replacement therapy lowers the risk of bone fracture in humans (postmenopause).

    “has additional benefits for preventing postmenopausal bone loss and reducing fracture risk.”

    Reviewpostmenopausefemales

    Hormone replacement therapy: an overview for South African pharmacists

    SA pharmaceutical journal.

  2. Hormone replacement therapy lowers the risk of bone fracture.

    “hormone replacement therapy, vitamin D supplements, and lifestyle changes, are critical for maintaining good bone health and lowering the risk of fracture”

    Review

    The Association Between Osteoporosis in Females Following Menopause and Vitamin D Deficiency

    Al-Esraa University College journal for medical sciences.

  3. Hormone replacement therapy lowers the risk of bone fracture in humans (early initiation) (20%-40% reduction in fracture risk).

    “early initiation of hormone replacement therapy reduces fracture risk by 20%-40%”

    Reviewearly initiationfemales

    Hormonal Shifts and Structural Strain: A Literature Review of Menopause and Perimenopause in Relation to Overuse Injuries and Stress Fractures

    Annals of rehabilitation medicine

  4. Hormone replacement therapy lowers the risk of bone fracture in women.

    “Menopausal hormone therapy has demonstrated efficacy in preventing bone loss and reducing fracture incidence when appropriately prescribed.”

    Reviewin womenfemales

    CRITICAL IMPLICATIONS OF FEMALE BONE METABOLISM IN ORTHOPEDICS: STATE OF THE ART

    Journal of ISAKOS : joint disorders & orthopaedic sports medicine

  5. Hormone replacement therapy lowers the risk of bone fracture in humans (particularly the combination of estradiol and dydrogesterone).

    “Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone.”

    Reviewparticularly the combination of estradiol and dydrogesterone

    Resolution of the VII International Forum of Experts on Menopausal Hormone Therapy

    Reproductive Endocrinology

  6. Hormone replacement therapy lowers the risk of bone fracture in humans.

    “Menopausal hormone therapy (MHT) improves menopausal symptoms and reduces the risk of osteoporosis and fracture.”

    Reviewfemales

    Demystifying menopausal hormone therapy prescribing

    Australian journal of general practice

  7. Hormone replacement therapy lowers the risk of bone fracture in humans.

    “an evidence-based option for reducing fracture risk in appropriate candidates”

    Reviewfemales

    Optimizing Healthspan in Women: A New Paradigm for Successful Aging through the Menopausal Transition

    Journal of menopausal medicine

  8. Hormone replacement therapy lowers the risk of bone fracture in postmenopausal women.

    “In postmenopausal women, both HRT and selectiveestrogen receptor modulators (SERMs) effectively reduce fracture risk and support bone health.”

    Reviewin postmenopausal womenfemales

    Impact of estroprogestin therapies on bone health from adolescence to postmenopause

    Journal of endocrinological investigation

  9. Hormone replacement therapy lowers the risk of bone fracture in humans (at sites such as the hip and vertebrae).

    “a decreased risk of fracture at sites such as the hip and vertebrae”

    Reviewat sites such as the hip and vertebraehip and vertebraefemales

    Comparative Effects of Hormone Replacement Therapy and Exercise on Bone Health in Postmenopausal Women: A Systematic Review

    Cureus

  10. Hormone replacement therapy lowers the risk of bone fracture in humans (postmenopausal women).

    “Recent research indicates that MHT significantly reduces the risk of fractures in women.”

    Reviewpostmenopausal womenfemales

    Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis

    Open life sciences

All 11

More on Bone fracture

Venous thromboembolism

upin humans7downin humans1mixedin humans1mixedin reviews1HR 1.59

10 studies
  1. Hormone replacement therapy is associated with venous thromboembolism in humans (1.8% vs 1.4%; HR 1.59, 95% CI 1.15–2.21).

    “HRT was associated with higher hazards of hospitalization, heart failure exacerbation, and venous thromboembolism”

    Humanspremature menopause; compared with no hormone replacement therapy after propensity score matching10 yearsfemales

    Hormone therapy not linked to fewer deaths after premature menopause

    AHA Scientific Sessions 2026 abstract

  2. Hormone replacement therapy is linked with a higher risk of venous thromboembolism in women with rheumatoid arthritis (aHR 1.92 (95% CI 1.19, 3.12)).

    “MHT use was associated with a 92% increased risk of VTE in RA [adjusted hazard ratio (aHR) 1.92 (95% CI 1.19, 3.12)]”

    Humansin women with rheumatoid arthritisfemales

    Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England

    Rheumatology advances in practice

  3. Hormone replacement therapy raises the risk of venous thromboembolism in humans (menopause).

    “Menopause hormone therapy increases venous thromboembolic risk, especially in the first year”

    Reviewmenopauseespecially in the first year

    Cardiovascular and thromboembolic risks of sex hormone therapy: from contraception to transgender care

    Annales d'endocrinologie

  4. Hormone replacement therapy raises the risk of venous thromboembolism in humans.

    “There is an increased risk of venous thromboembolism (VTE) with oral formulations”

    Revieworal

    Management of menopausal hormone therapy

    Current opinion in obstetrics & gynecology

  5. Hormone replacement therapy lowers the risk of venous thromboembolism in humans (menopause hormone therapy).

    “The risk of venous thromboembolism is minimized by the transdermal route.”

    Reviewmenopause hormone therapytransdermalfemales

    HORMONE THERAPY IN MENOPAUSE: EVALUATION OF BENEFITS AND RISKS

    Asclepius International Journal of Scientific Health Science

  6. Hormone replacement therapy is associated with venous thromboembolism in humans among multiple VTE risk factors.

    “Other studies examined HRT among multiple VTE risk factors, with inconsistent findings.”

    Reviewamong multiple VTE risk factors

    Perioperative hormone replacement therapy (HRT) and venous thromboembolism risk: a scoping review of available evidence and guidance

    JRSM open

  7. Hormone replacement therapy raises the risk of venous thromboembolism in humans (postmenopausal women).

    “there are also risks related to specific outcomes, such as venous thromboembolism (TEV).”

    Reviewpostmenopausal womenfemales

    Influence of hormone therapy on cardiovascular health in postmenopausal women

    Revista JRG de Estudos Acadêmicos

  8. Hormone replacement therapy raises the risk of venous thromboembolism in humans (two- to four-fold increased risk).

    “Oral menopause hormone therapy (MHT) is associated with a two- to four-fold increased risk of venous thromboembolism (VTE).”

    Revieworalfemales

    Is the risk of venous thromboembolic disease truly an absolute contraindication for menopause hormone therapy?

    Ceska gynekologie

  9. Hormone replacement therapy is associated with venous thromboembolism (risk depends on HRT type and route of administration).

    “distinguishing between different types and routes of administration when considering the suitability of HRT”

    Reviewrisk depends on HRT type and route of administrationsynthetic and body-identical types

    Exploring the potential for a set of UK hormone replacement therapy eligibility guidelines: A suggested proposal on the topic of venous thromboembolism

    Post reproductive health

  10. Hormone replacement therapy raises the risk of venous thromboembolism in humans (as reported by the Women's Health Initiative randomised placebo-controlled trial).

    “They suggested that hormone replacement therapy (HRT) use increased the risk of cardiovascular disease and venous thromboembolism including pulmonary embolism and deep vein thrombosis”

    Reviewas reported by the Women's Health Initiative randomised placebo-controlled trialfemales

    Hormone replacement therapy in women with history of thrombosis or a thrombophilia

    Post reproductive health

More on Venous thromboembolism

Alzheimer's disease

downin humans7upin humans2mixedin reviews1RR 0.78–0.81

9 studies
  1. Hormone replacement therapy is associated with Alzheimer's disease in humans (Initiated within 10 years of menopause) (1.4% vs 1.7%; RR 0.81, 95% CI 0.70-0.92).

    “HRT was associated with lower risks of stroke/TIA (6.4% vs 7.5%; RR 0.86, 95% CI 0.81-0.91; p<0.001) and AD (1.4% vs 1.7%; RR 0.81, 95% CI 0.70-0.92; p=0.002).”

    HumansInitiated within 10 years of menopausefemales

    Early Hormone Replacement Therapy and Cognitive Outcomes in Postmenopausal Women

    AHA Scientific Sessions 2026 abstract

  2. Hormone replacement therapy is linked with a lower risk of Alzheimer's disease in humans (HR 0.804, 95% CI 0.696-0.928).

    “AD (HR [95%CI], 0.804 [0.696-0.928])”

    Humansfemalesn = 233,896

    Associations of oral contraceptives and hormone replacement therapy with incident dementia risk: a population-based cohort study

    Translational psychiatry

  3. Hormone replacement therapy is linked with a lower risk of Alzheimer's disease in postmenopausal women with chronic kidney disease; adjusted Cox regression (HR 0.80; 95% CI 0.77-0.82).

    “Alzheimer's disease: HR 0.80; 95% CI 0.77-0.82; p < 0.001”

    Humansin postmenopausal women with chronic kidney disease; adjusted Cox regressionfemalesn = 755,426

    Menopausal hormone therapy and risk for dementia in women with CKD: A nationwide observational cohort study

    Nephrology (Carlton, Vic.)

  4. Hormone replacement therapy is associated with Alzheimer's disease in women.

    “Exposure to HRT may modify the development of AD; however, data are weak and the influence of timing, duration, type of HRT, and ethnic, socioeconomic, educational and genomic factors such as APOE genotype, requires further clarification.”

    Reviewin women

    Menopause and Alzheimer's disease: can hormone replacement therapy modify the risk? A narrative review

    BMC women's health

  5. Hormone replacement therapy is associated with Alzheimer's disease in humans (women with a uterus; compared with placebo or no menopausal hormone therapy) (HR 1.14, 95% CI 1.02–1.29).

    “Initiating MHT in women with a uterus around the age of menopause increased the risk of Alzheimer’s disease slightly, by over 10%”

    Reviewwomen with a uterus; compared with placebo or no menopausal hormone therapysystemicfemalesn = 134,865

    Menopausal hormone therapy at age 45 to 60 years old, future dementia or cognitive decline: Systematic review and meta-analysis

    medRxivPreprint

  6. Hormone replacement therapy raises the risk of Alzheimer's disease in humans after the menopausal transition.

    “administration of MHT after the menopausal transition is associated with modest increased risk of Alzheimer's.”

    Reviewafter the menopausal transitionfemales

    Sex Hormone Therapies and Alzheimer's Disease: Prevention vs Treatment

    AAIC 2025 abstract

  7. Hormone replacement therapy lowers the risk of Alzheimer's disease in humans (for menopause-related symptoms).

    “Medical informatic analyses of real‐world menopausal hormone therapy (MHT) for menopause‐related symptoms indicates a significant reduction in risk of Alzheimer's disease.”

    Reviewfor menopause-related symptomsfemales

    Sex Hormone Therapies and Alzheimer's Disease: Prevention vs Treatment

    AAIC 2025 abstract

  8. Hormone replacement therapy is associated with Alzheimer's disease in humans (Pooled observational studies) (RR 0.78, 95% CI 0.64–0.95).

    “observational studies indicate a reduced risk of AD [RR = 0.78, 95% C.I. 0.64-0.95, p = 0.013]”

    ReviewPooled observational studies

    Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia

    Frontiers in aging neuroscience

  9. Hormone replacement therapy lowers the risk of Alzheimer's disease in humans (early and premature menopause).

    “Menopausal hormone therapy from menopause to the age of 60 years may provide a "window of opportunity" to reduce the risk of mild cognitive impairment (MCI) and AD in later life.”

    Reviewearly and premature menopausefemales

    Cognitive Decline in Early and Premature Menopause

    International journal of molecular sciences

  10. Hormone replacement therapy lowers the risk of Alzheimer's disease in humans (peri-menopausal women who used HRT).

    “peri-menopausal women who used hormone replacement therapy (HRT) had a reduced AD risk”

    Reviewperi-menopausal women who used HRTfemales

    Accelerated Ovarian Failure as a Unique Model to Study Peri-Menopause Influence on Alzheimer's Disease

    Frontiers in aging neuroscience

More on Alzheimer's disease

Dementia

downin humans4upin humans4mixedin humans1HR 0.74–1.35

8 studies
  1. Hormone replacement therapy is linked with a lower risk of dementia in women with surgical menopause (HR 0.74, 95% CI 0.65-0.84).

    “with stronger associations in surgical menopause (0.74, 0.65-0.84)”

    Humansin women with surgical menopause≥1 yearfemales

    Hormone replacement therapy and dementia risk among postmenopausal women: Identifying responsive subgroups in the UK Biobank

    Alzheimer's & dementia : the journal of the Alzheimer's Association

  2. Hormone replacement therapy is linked with a lower risk of dementia in humans (HR 0.897, 95% CI 0.811-0.992).

    “HRT was associated with decreased risks of ACD (HR [95%CI], 0.897 [0.811-0.992])”

    Humansfemalesn = 233,896

    Associations of oral contraceptives and hormone replacement therapy with incident dementia risk: a population-based cohort study

    Translational psychiatry

  3. Hormone replacement therapy is linked with a higher risk of dementia in humans (20.04 vs 15.79 per 1,000; adjusted HR 1.35 (95% CI 1.13-2.62)).

    “the cumulative incidence of dementia for the HRT cohort (20.04 per 1,000) was significantly higher than the corresponding cumulative incidence for the comparison cohort (15.79 per 1,000)”

    Humansfemalesn = 70,048

    Use of Hormone Replacement Therapy and Risk of Dementia: A Nationwide Cohort Study

    Neurology

  4. Hormone replacement therapy lowers the risk of dementia in humans (initiation within five years of menopause) (pooled aRR 0.66, 95% CI 0.53 to 0.83, p = 0.0003).

    “Initiation within five years of menopause was associated with a clinically meaningful reduction in dementia risk (pooled aRR 0.66, 95% CI 0.53 to 0.83”

    Reviewinitiation within five years of menopause

    Impact of Menopausal Hormone Therapy on cognitive function and dementia Risk: A systematic review and meta-analysis focusing on the timing hypothesis and administration route

    Middle East Current Psychiatry

  5. Hormone replacement therapy raises the risk of dementia in humans (late initiation).

    “initiation after age 65 or following prolonged hypoestrogenism is associated with increased dementia risk in some randomized trials”

    Reviewlate initiationfemales

    MENOPAUSAL HORMONE THERAPY AND DEMENTIA RISK: AN INTEGRATED NEUROVASCULAR AND PRECISION MEDICINE PERSPECTIVE

    International Journal of Innovative Technologies in Social Science

  6. Hormone replacement therapy is associated with dementia in humans.

    “The available evidence indicates that estrogen plays a significant role in influencing dementia risk, with studies demonstrating both beneficial and detrimental effects of HRT.”

    Reviewfemales

    Hormone Replacement Therapy and Alzheimer's Disease: Current State of Knowledge and Implications for Clinical Use

    Journal of Alzheimer's disease : JAD

  7. Hormone replacement therapy raises the risk of dementia in humans (RR 1.38, 95% CI 1.16–1.64).

    “Randomized controlled trials conducted in postmenopausal women ages 65 and older show an increased risk of dementia with HT use compared with placebo”

    ReviewPostmenopausal women; pooled randomized controlled trials comparing hormone therapy with placebofemales

    Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer's disease and dementia

    Frontiers in aging neuroscience

  8. Hormone replacement therapy raises the risk of dementia in humans (initiated in predominantly comorbid postmenopausal women) (approximately 2-fold).

    “WHIMS) reported an approximately 2-fold increased risk of dementia/Alzheimer's disease if MHT comprising conjugated equine estrogens and medroxyprogesterone acetate was initiated in predominantly comorbid postmenopausal women above age 65.”

    Reviewinitiated in predominantly comorbid postmenopausal womenconjugated equine estrogens and medroxyprogesterone acetatefemales

    Cognitive health after menopause: Does menopausal hormone therapy affect it?

    Best practice & research. Clinical endocrinology & metabolism

  9. Hormone replacement therapy lowers the risk of dementia in humans (11-33%).

    “The majority of studies found a risk reducing impact of MHT by 11-33%.”

    Reviewfemales

    Cognitive health after menopause: Does menopausal hormone therapy affect it?

    Best practice & research. Clinical endocrinology & metabolism

More on Dementia

Mortality

downin humans7upin humans1HR 0.62–1.25

8 studies
  1. Hormone replacement therapy is linked with a lower risk of mortality in humans (HR 0.65 (95% CI 0.47-0.88)).

    “HRT significantly correlated with a reduced risk of all-cause (HR: 0.65, 95% CI: 0.47-0.88; P = 0.006)”

    Humans

    Hormone replacement therapy through the lens of epigenetic clock: estrogen signals, glycemic status, and lifespan

    Biology of sex differences

  2. Hormone replacement therapy is linked with a lower risk of mortality in women with heart failure.

    “Among women with HF, OC, and MHT use were associated with lower mortality”

    Humansin women with heart failurefemales

    Reproductive history, hormonal exposure, and risk of heart failure in postmenopausal women: a Korean nationwide study

    European heart journal

  3. Hormone replacement therapy is associated with mortality in humans (Adjusted HR 0.96 (95% CI 0.93 to 0.98)).

    “corresponding to an adjusted hazard ratio of 0.96 (95% confidence interval (CI) 0.93 to 0.98).”

    HumanssystemicMedian follow-up 14.3 yearsfemalesn = 876,805

    Menopausal hormone therapy and long term mortality: nationwide, register based cohort study

    BMJ (Clinical research ed.)

  4. Hormone replacement therapy is associated with mortality in humans (HRT initiation within 5 years of menopause) (HR 0.62, 95% CI 0.48–0.80).

    “HRT use within 5 years of menopause was associated with decreased MACE and all-cause mortality”

    HumansHRT initiation within 5 years of menopauseMedian follow-up of 14 yearsfemalesn = 2,427

    Hormone Replacement Therapy and Cardiovascular Outcomes by Race and Ethnicity: MESA (Multi-Ethnic Study of Atherosclerosis)

    JACC. Advances

  5. Hormone replacement therapy is associated with mortality in humans (women veterans; compared with no menopausal hormone therapy) (HR 1.25, 95% CI 1.13–1.39).

    “the HT cohort had significantly higher rates of CVD compared to the non-HT cohort (22.4% vs. 11.7%, P < 0.001), and all-cause mortality”

    Humanswomen veterans; compared with no menopausal hormone therapyoral or transdermal estrogen-containing product or combined estrogen-progestinfemales

    Association of menopausal hormone therapy with incident cardiovascular disease in women veterans

    European heart journal. Quality of care & clinical outcomes

  6. Hormone replacement therapy is linked with a lower risk of mortality in humans (combined HRT users compared with non-users, matched on age and general practice) (HR 0.91 (95% CI 0.88-0.94)).

    “The adjusted hazard ratio (HR) of overall all-cause mortality in combined HRT users was 0.91 (95% CI 0.88-0.94)”

    Humanscombined HRT users compared with non-users, matched on age and general practicecombinedfemales

    The effect of hormone replacement therapy on the survival of UK women: a retrospective cohort study 1984-2017

    BJOG : an international journal of obstetrics and gynaecology

  7. Hormone replacement therapy lowers the risk of mortality in women who start HT before age 60.

    “women who start HT before age 60 appear to have a decreased mortality risk.”

    Reviewin women who start HT before age 60menopausal hormone therapyfemales

    Efficacy and safety of estrogen therapy for prevention of osteoporosis in postmenopausal women

    Women's health (London, England)

  8. Hormone replacement therapy lowers the risk of mortality in women with existing heart failure (RR 0.65; 95% CI 0.49–0.87).

    “in women with existing HF, HRT was linked to a 35% reduction in all-cause mortality (RR 0.65; 95% CI, 0.49–0.87; p = 0.003)”

    Reviewin women with existing heart failurefemales

    Hormone Replacement Therapy and Heart Failure with Mildly Reduced Ejection Fraction in Postmenopausal Women: A Systematic Review

    AHA Scientific Sessions 2025 abstract

Stroke

upin humans5downin humans2mixedin humans1HR 0.71–2.695

8 studies
  1. Hormone replacement therapy is linked with a lower risk of stroke in humans (HR 0.85 [0.82-0.89]).

    “Menopausal hormone therapy use was associated with lower risk of stroke (HR 0.85 [0.82 - 0.89]) and CHD (HR 0.80 [0.76 - 0.84]).”

    Humansfemales

    Associations of endogenous and exogenous hormonal exposures and cardiovascular disease in women - A FinnGen study

    medRxivPreprint

  2. Hormone replacement therapy is linked with a higher risk of stroke in humans (initiation at 65 years or older) (HR 2.695, 95% CI 2.358-3.079).

    “cerebrovascular accident (HR: 2.695, 95% CI: 2.358-3.079)”

    Humansinitiation at 65 years or olderfemales

    Health outcomes of hormone therapy initiated or continued after age 65

    Menopause (New York, N.Y.)

  3. Hormone replacement therapy is associated with stroke in humans (Prior pre-eclampsia; compared with MHT non-users) (HR 0.71, 95% CI 0.63–0.81).

    “stroke events (HR 0.71, 95 % CI 0.63-0.81) in comparison with non-users with prior pre-eclampsia.”

    HumansPrior pre-eclampsia; compared with MHT non-usersMean follow-up 13.3 yearsfemales

    Prior pre-eclampsia does not diminish the vascular protective effect of menopausal hormone therapy

    Maturitas

  4. Hormone replacement therapy is associated with stroke in humans (varies depending on formulation, route, age, and health).

    “menopausal hormone therapy, a leading approach to managing menopausal symptoms, has implications for stroke risk, which varies depending on the menopausal hormone therapy formulation, route of delivery, and the age”

    Reviewvaries depending on formulation, route, age, and health

    Menopause and Its Implications for Stroke in Women

    Stroke

  5. Hormone replacement therapy raises the risk of stroke in humans (HR 1.14, 95% CI 1.05–1.24).

    “HRT use was associated with a modest increase in stroke risk (HR 1.14; 95% CI 1.05–1.24).”

    Reviewfemales

    Cardiovascular and Cancer Risks Associated with Different Hormone Replacement Therapy Regimens: A Systematic Review and Meta-Analysis (2020–2025 Evidence)

    Journal of medical & health sciences review.

  6. Hormone replacement therapy raises the risk of stroke in humans (delayed initiation).

    “delayed initiation may increase risks such as stroke and venous thromboembolism”

    Reviewdelayed initiationfemales

    Hormone replacement therapy and cardiovascular risk in postmenopausal women

    European heart journal open

  7. Hormone replacement therapy raises the risk of stroke in humans (Perimenopausal or postmenopausal women; meta-analyses of randomized controlled trials) (RR 1.17, 95% CI 1.05 to 1.29).

    “but harmful for stroke (17 trials, 37,272 women, RR 1.17, 95% CI 1.05 to 1.29, p = 0.027)”

    ReviewPerimenopausal or postmenopausal women; meta-analyses of randomized controlled trialsfemalesn = 37,272

    Menopausal hormone therapy and women's health: An umbrella review

    PLoS medicine

  8. Hormone replacement therapy raises the risk of stroke in humans.

    “hormone replacement therapy use, and younger age at menopause all increase the risk of stroke”

    Reviewfemales

    Stroke in Women

    Continuum (Minneapolis, Minn.)

More on Stroke

Type 2 diabetes

downin humans4upin humans1RR 0.83

5 studies
  1. Hormone replacement therapy is linked with a lower risk of type 2 diabetes in humans (menopause at age ≤60 years; propensity-matched new users vs non-users) (HR 0.595, 95% CI 0.575-0.615).

    “lower hazards of T2DM (events: 3517 vs 4580; crude incidence: 4.20% vs 5.47%; HR: 0.595, 95% CI: 0.575-0.615)”

    Humansmenopause at age ≤60 years; propensity-matched new users vs non-usersestrogen and/or progestogenfemalesn = 83,670

    Long-term systemic outcomes of postmenopausal hormone replacement therapy by age at menopause: a real-world cohort study

    Human reproduction open

  2. Hormone replacement therapy is linked with a lower risk of type 2 diabetes in humans after chemoradiotherapy for cervical cancer (5.3% vs 9.8%; HR 0.59 (95% CI 0.32-0.81)).

    “Compared with nonhormone therapy users, hormone therapy use was associated with a significantly lower risk of type 2 diabetes mellitus (5.3% vs 9.8%; hazard ratios, 0.59; 95% confidence interval, 0.32-0.81)”

    Humansafter chemoradiotherapy for cervical cancerfemales

    Hormones linked to benefits in young advanced cervical cancer cohort

    American journal of obstetrics and gynecology

  3. Hormone replacement therapy is linked with a lower risk of type 2 diabetes in humans (peri-menopausal women with pre-existing MASLD) (HR 0.90, 95% CI 0.84-0.96).

    “reduced risk of cardiometabolic outcomes: T2D (0.90; 0.84, 0.96)”

    Humansperi-menopausal women with pre-existing MASLD5 yearsfemales

    Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri-Menopausal MASLD

    Liver international : official journal of the International Association for the Study of the Liver

  4. Hormone replacement therapy is linked with a higher risk of type 2 diabetes in humans (HR 1.19 [1.14;1.24]).

    “ever used hormonal replacement therapy (HR 1.19 [1.14;1.24]) were related to a higher T2DM risk”

    Humansfemales

    Reproductive factors, genetic susceptibility and risk of type 2 diabetes: A prospective cohort study

    Diabetes & metabolism

  5. Hormone replacement therapy lowers the risk of type 2 diabetes in humans (women without type 2 diabetes) (RR 0.83, 95% CI 0.75-0.92).

    “lower risk of new-onset type 2 diabetes (14 studies: N=1,450,134, risk ratio 0.83 [95% CI 0.75, 0.92]; very low CoE]”

    Reviewwomen without type 2 diabetesfemales

    Menopause hormone therapy and type 2 diabetes risk and prognosis: systematic review and meta-analyses

    Diabetologia

More on Type 2 diabetes

Cognitive function

upin humans3mixedin humans2

5 studies
  1. Hormone replacement therapy is associated with cognitive function in humans.

    “age, education, HRT use, age at menopause, alcohol consumption, and diet were associated with cognitive function at a single later time point”

    Humansfemales

    Hormone replacement therapy, menopausal age and lifestyle variables are associated with better cognitive performance at follow-up but not cognition over time in older-adult women irrespective of APOE4 carrier status and co-morbidities

    Frontiers in dementia

  2. Hormone replacement therapy is associated with cognitive function in Latin American and Caribbean women.

    “Some studies suggested favorable associations between menopausal hormone therapy use and cognitive outcomes.”

    Reviewin Latin American and Caribbean womenfemales

    Reproductive life stages and cognitive outcomes: a systematic review in Latin American and Caribbean women

    Frontiers in aging neuroscience

  3. Hormone replacement therapy is associated with cognitive function in humans (initiation within approximately five years of menopause).

    “initiation of MHT within approximately five years of menopause appears cognitively neutral and may confer modest benefit in selected populations”

    Reviewinitiation within approximately five years of menopausefemales

    MENOPAUSAL HORMONE THERAPY AND DEMENTIA RISK: AN INTEGRATED NEUROVASCULAR AND PRECISION MEDICINE PERSPECTIVE

    International Journal of Innovative Technologies in Social Science

  4. Hormone replacement therapy is associated with cognitive function in humans.

    “The cognitive benefits associated with hormone replacement therapy (HRT) are believed to be linked to estrogen's neuroprotective effects”

    Reviewfemales

    Influence of the Onset of Menopause on the Risk of Developing Alzheimer's Disease

    Cureus

  5. Hormone replacement therapy is associated with cognitive function in humans (menopausal women).

    “The studies conducted to date have reported conflicting results regarding the effects of HT on cognition.”

    Reviewmenopausal womenfemales

    Menopause and cognitive impairment: A narrative review of current knowledge

    World journal of psychiatry

All 251

What acts on hormone replacement therapy?

1

Studies name bilateral salpingo-oophorectomy as acting on hormone replacement therapy.

Bilateral salpingo-oophorectomy

upin humans1

1 study
  1. Bilateral salpingo-oophorectomy is linked with higher hormone replacement therapy in humans during benign hysterectomy in postmenopausal individuals (aHR 2.04 (95% CI 1.92-2.17)).

    “The likelihood of starting menopausal hormone therapy after surgery was significantly higher for those who had hysterectomy with bilateral oophorectomy compared to hysterectomy with ovarian conservation (adjusted hazard ratio, 2.04; 95% confidence interval, 1.92-2.17).”

    Humansduring benign hysterectomy in postmenopausal individualsfemalesn = 18,676

    Health outcomes following oophorectomy during benign hysterectomy in those who are in postmenopausal ages: a population-based study

    American journal of obstetrics and gynecology

More on Bilateral salpingo-oophorectomy

Funding

18 grants since 2019

National Institute on Aging$5MNational Institute for Health Research£2.4MNational Heart, Lung, and Blood Institute$1.1M

Contains public sector information licensed under the Open Government Licence v3.0.

Latest

Dec 2025: 38Jan 2026: 35Feb 2026: 39Mar 2026: 46Apr 2026: 45May 2026: 40Jun 2026: 50Jul 2026: 48Aug 2026: 50Sep 2026: 37Oct 2026: 45Nov 2026: 27500 papers in 12 months
Human Reproduction Open

Longer reproductive span linked to lower osteoporosis risk

Compared with under 30 years, at least 40 years between first period and menopause was linked to lower osteoporosis risk (hazard ratio 0.82).Compared with under 30 years, at least 40 years between first period and menopause was linked to lower osteoporosis risk (hazard ratio 0.82).

Cohort · 2,147,384 peopleOsteoporosis

See all 1,018 papers on hormone replacement therapy